Jessica Maria Heijdra

Jessica Maria Heijdra

Auto-generated profile, based on publicly available information

Jessica Maria Heijdra

Department of Pediatric Hematology Erasmus MC – Sophia Children's Hospital, University Medical Center Rotterdam Rotterdam The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2018 in Haemophilia
Verified
Journal Article
Open access
PDF file
HHH. C. A. M. Hazendonk
H. C. A. M. Hazendonk
JHJ. M. Heijdra
J. M. Heijdra
NJN. C. B. de Jager
N. C. B. de Jager
HVH. C. Veerman
H. C. Veerman
JBJ. Boender
J. Boender
TGthe “OPTI‐CLOT” and “WIN” study group
the “OPTI‐CLOT” and “WIN” study group
Introduction: Patients with Von Willebrand disease (VWD) are regularly treated with VWF‐containing concentrates in case of acute bleeding, trauma and dental or surgical procedures.Aim: In this multicentre retrospective study, current perioperative management with a von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate (Haemate® P) in patients with VWD was evaluated.Patients/Methods: Patients with VWD undergoing minor or major surgery between 2000 and 2015, requiring treatment with a VWF/FVIII concentrate (Haemate® P), were included. Achieved VWF activity (VWF:Act) and FVIII during FVIII‐based treatment regimens were compared to predefined target levels in national guidelines.Results: In total, 103 patients with VWD (148 surgeries) were included: 54 type 1 (73 surgeries), 43 type 2 (67 surgeries) and 6 type 3 (8 surgeries). Overall, treatment resulted in high VWF:Act and FVIII levels, defined as ≥0.20 IU/mL above predefined levels. In patients with type 1 VWD, respectively, 65% and 91% of trough VWF:Act and FVIII levels were higher than target levels. In patients with type 2 and type 3 VWD, respectively, 53% and 57% of trough VWF:Act and 72% and 73% of trough FVIII levels were higher than target level. Furthermore, FVIII accumulation over time was observed, while VWF:Act showed a declining trend, leading to significantly higher levels of FVIII than VWF:Act.Conclusion: High VWF:Act and accumulation of FVIII were observed after perioperative FVIII‐based replacement therapy in patients with VWD, both underlining the necessity of personalization of dosing regimens to optimize perioperative treatment.

8 August 2017 in Drugs
Verified
Journal Article
Open access
PDF file
JHJessica M. Heijdra
Jessica M. Heijdra
MCMarjon H. Cnossen
Marjon H. Cnossen
FLFrank W. G. Leebeek
Frank W. G. Leebeek
Von Willebrand disease (VWD) is the most common inherited bleeding disorder with an estimated prevalence of ~1% and clinically relevant bleeding symptoms in approximately 1:10,000 individuals. VWD is caused by a deficiency and/or defect of von Willebrand factor (VWF). The most common symptoms are mucocutaneous bleeding, hematomas, and bleeding after trauma or surgery. For decades, treatment to prevent or treat bleeding has consisted of desmopressin in milder cases and of replacement therapy with plasma-derived concentrates containing VWF and Factor VIII (FVIII) in more severe cases. Both are usually combined with supportive therapy, e.g. antifibrinolytic agents, and maximal hemostatic measures. Several developments such as the first recombinant VWF concentrate, which has been recently licensed for VWD, will make a more “personalized” approach to VWD management possible. As research on new treatment strategies for established therapies, such as population pharmacokinetic-guided dosing of clotting factor concentrates, and novel treatment modalities such as aptamers and gene therapy are ongoing, it is likely that the horizon to tailor therapy to the individual patients’ needs will be extended, thus, further improving the already high standard of care in VWD in most high-resource countries.

20 September 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
FAFerdows Atiq
Ferdows Atiq
JHJessica Maria Heijdra
Jessica Maria Heijdra
FSFleur Snijders
Fleur Snijders
JBJohan Boender
Johan Boender
EKEva Kempers
Eva Kempers
FLFrank W. G. Leebeek
Frank W. G. Leebeek
Patients with type 1 and type 2 von Willebrand disease (VWD) can be treated with desmopressin. Although a previous study has shown that the location of the causative VWF gene variant is associated with desmopressin response in type 1 VWD, the association between variants in the VWF gene and desmopressin response is not yet fully understood. Our primary aim was to compare desmopressin response in type 1 VWD patients with and without a VWF gene variant. Secondly, we investigated whether desmopressin response depends on specific VWF gene variants in type 1 and type 2 VWD. We included 250 patients from the Willebrand in the Netherlands study: 72 type 1 without a VWF gene variant, 108 type 1 with a variant, 45 type 2A, 16 type 2M, and 9 type 2N patients. VWF gene was analyzed with ion semiconductor sequencing and Multiplex Ligation-dependent Probe Amplification. Complete response to desmopressin was observed in all type 1 VWD patients without a variant, 64.3% of type 1 patients with a variant, and 31.3% of type 2 patients (P < .001). Despite a large interindividual variability in desmopressin response, patients with the same variant had comparable desmopressin responses. For instance, in 6 type 1 patients with exon 4 to 5 deletion, mean VWF activity at 1 hour after desmopressin was 0.81 IU/mL, with a coefficient of variation of 22.9%. In conclusion, all type 1 VWD patients without a VWF gene variant respond to desmopressin. In type 1 and type 2 VWD patients with a VWF variant, desmopressin response highly depends on the VWF gene variants.

8 March 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
LBLaura H. Bukkems
Laura H. Bukkems
JHJessica M. Heijdra
Jessica M. Heijdra
NJNico C. B. de Jager
Nico C. B. de Jager
HHHendrika C. A. M. Hazendonk
Hendrika C. A. M. Hazendonk
KFKarin Fijnvandraat
Karin Fijnvandraat
RMRon A. A. Mathôt
Ron A. A. Mathôt
Recent studies have reported that patients with von Willebrand disease treated perioperatively with a von Willebrand factor (VWF)/factor VIII (FVIII) concentrate with a ratio of 2.4:1 (Humate P/Haemate P) often present with VWF and/or FVIII levels outside of prespecified target levels necessary to prevent bleeding. Pharmacokinetic (PK)-guided dosing may resolve this problem. As clinical guidelines increasingly recommend aiming for certain target levels of both VWF and FVIII, application of an integrated population PK model describing both VWF activity (VWF:Act) and FVIII levels may improve dosing and quality of care. In total, 695 VWF:Act and 894 FVIII level measurements from 118 patients (174 surgeries) who were treated perioperatively with the VWF/FVIII concentrate were used to develop this population PK model using nonlinear mixed-effects modeling. VWF:Act and FVIII levels were analyzed simultaneously using a turnover model. The protective effect of VWF:Act on FVIII clearance was described with an inhibitory maximum effect function. An average perioperative VWF:Act level of 1.23 IU/mL decreased FVIII clearance from 460 mL/h to 264 mL/h, and increased FVIII half-life from 6.6 to 11.4 hours. Clearly, in the presence of VWF, FVIII clearance decreased with a concomitant increase of FVIII half-life, clarifying the higher FVIII levels observed after repetitive dosing with this concentrate. VWF:Act and FVIII levels during perioperative treatment were described adequately by this newly developed integrated population PK model. Clinical application of this model may facilitate more accurate targeting of VWF:Act and FVIII levels during perioperative treatment with this specific VWF/FVIII concentrate (Humate P/Haemate P).

5 May 2020 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
LBLaura H. Bukkems
Laura H. Bukkems
JHJessica M. Heijdra
Jessica M. Heijdra
MMMary Mathias
Mary Mathias
PCPeter W. Collins
Peter W. Collins
CHCharles R. M. Hay
Charles R. M. Hay
FCfor UK-EHL Outcomes Registry OPTI-CLOT Collaboration
for UK-EHL Outcomes Registry OPTI-CLOT Collaboration
Background The currently published population pharmacokinetic (PK) models used for PK-guided dosing in hemophilia patients are based on clinical trial data and usually not externally validated in clinical practice. The aim of this study was to validate a published model for recombinant factor VIII-Fc fusion protein (rFVIII-Fc) concentrate and to develop an enriched model using independently collected clinical data if required. Methods Clinical data from hemophilia A patients treated with rFVIII-Fc concentrate (Elocta) participating in the United Kingdom Extended Half-Life Outcomes Registry were collected. The predictive performance of the published model was assessed using mean percentage error (bias) and mean absolute percentage error (inaccuracy). An extended population PK model was developed using nonlinear mixed-effects modeling (NONMEM). Results A total of 43 hemophilia A patients (FVIII ≤ 2 IU/dL), aged 5 to 70 years, were included. The prior model was able to predict the collected 244 rFVIII-Fc levels without significant bias (–1.0%, 95% CI: –9.4 to 7.3%) and with acceptable accuracy (12.9%). However, clearance and central distribution volume were under predicted in patients <12 years, which was expected as this age group was not represented in the previous model population. An enriched population PK model was constructed, which was able to successfully characterize PK profiles of younger children. Conclusion We concluded that the existing rFVIII-Fc population PK model is valid for patients ≥ 12 years. However, it is not reliable in younger patients. Our alternative model, constructed from real world patient data including children, allows for better description of patients ≥5 years. L.H.B. and R.A.A.M. analyzed the data and developed the population pharmacokinetic model. J.M.H. collected and checked all clinical data from the EHL registry. R.A.A.M., M.H.C. and P.C. designed and supervised the study, while M.M., P.W.C., C.R.M.H., F.W.G.L., K.M., and K.F. gave critical guidance. Patient inclusion in the UK EHL registry was monitored by M.M., P.W.C., C.R.M.H., R.C.T., S.M., B.M., G.E., B.B., N.C., J.P., and S.A. The clinical case was treated by K.F. All authors contributed substantially to the writing and critical revision of the manuscript and approved the final draft. This study is a collaboration between the international multicenter OPTI-CLOT consortium (Patient tailOredPharmacokineTIc-guided dosing of CLOTting factor concentrate and desmopressin in bleeding disorders) and the United Kingdom – Extended Half-Life (UK-EHL) Outcome registry. OPTI-CLOT aims to implement PK-guided dosing of clotting factor concentrates by initiating studies that emphasize the impact of PK-guided dosing, by constructing prophylactic and on-demand population PK models, and by evaluating the cost-effectiveness of a PK-guided approach. The UK-EHL Outcome registry aims to evaluate the impact of EHLs on real world outcomes for patients with hemophilia and develop an evidence base for the introduction of new clinical strategies for improved patient outcomes. A list of the members of the “OPTI-CLOT” and UK-EHL outcome registry programs are available in [Supplementary Appendix A] (available in the online version). * Shared first and last authorship.

1 June 2020 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
IMIris van Moort
Iris van Moort
LBLaura H. Bukkems
Laura H. Bukkems
JHJessica M. Heijdra
Jessica M. Heijdra
RSRoger E. G. Schutgens
Roger E. G. Schutgens
BGBritta A. P. Laros-Van Gorkom
Britta A. P. Laros-Van Gorkom
FGfor the OPTI-CLOT Study Group
for the OPTI-CLOT Study Group
Background von Willebrand factor (VWF) is crucial for optimal dosing of factor VIII (FVIII) concentrate in hemophilia A patients as it protects FVIII from premature clearance. To date, it is unknown how VWF behaves and what its impact is on FVIII clearance in the perioperative setting. Aim To investigate VWF kinetics (VWF antigen [VWF:Ag]), VWF glycoprotein Ib binding (VWF:GPIbM), and VWF propeptide (VWFpp) in severe and moderate perioperative hemophilia A patients included in the randomized controlled perioperative OPTI-CLOT trial. Methods Linear mixed effects modeling was applied to analyze VWF kinetics. One-way and two-way analyses of variance were used to investigate perioperative VWFpp/VWF:Ag ratios and associations with surgical bleeding. Results Fifty-nine patients with median age of 48.8 years (interquartile range: 34.8–60.0) were included. VWF:Ag and VWF:GPIbM increased significantly postoperatively. Blood type non-O or medium risk surgery were associated with higher VWF:Ag and VWF:GPIbM levels compared with blood type O and low risk surgery. VWFpp/VWF:Ag was significantly higher immediately after surgery than 32 to 57 hours after surgery (p < 0.001). Lowest VWF:Ag quartile (0.43–0.92 IU/mL) was associated with an increase of FVIII concentrate clearance of 26 mL/h (95% confidence interval: 2–50 mL/h) compared with highest VWF antigen quartile (1.70–3.84 IU/mL). VWF levels were not associated with perioperative bleeding F(4,227) = 0.54, p = 0.710. Conclusion VWF:Ag and VWF:GPIbM levels increase postoperatively, most significantly in patients with blood type non-O or medium risk surgery. Lower VWF antigen levels did not lead to clinically relevant higher FVIII clearance. VWF:Ag or VWF:GPIbM levels were not associated with perioperative hemorrhage.